Information Provided By: 
Fly News Breaks for March 21, 2017
MD
Mar 21, 2017 | 07:38 EDT
As previously reported, Baird analyst Whit Mayo downgraded MEDNAX to Neutral from Outperform citing a balanced risk/reward, weak organic growth, its sector high historical and relative EBITDA valuation, and a current setup that appears to be reliant on M&A. Mayo maintained his $72 price target on MEDNAX shares.
News For MD From the Last 2 Days
There are no results for your query MD
